Loading...

Home
Stock
NBIX

NBIX News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

NBIX News

Neurocrine Shares Drop 8% After Mixed Earnings Despite Strong Ingrezza Sales

Feb 12 2026Newsfilter

Neurocrine Reports Q4 Earnings Miss Amid Strong Sales Growth

Feb 12 2026Benzinga

Wall Street Analysts Adjust Ratings

Feb 12 2026Benzinga

Neurocrine Biosciences Q4 2025 Earnings Call Highlights

Feb 12 2026seekingalpha

Neurocrine Biosciences Q4 Earnings Analysis

Feb 11 2026seekingalpha

Neurocrine Biosciences Reports Strong 2025 Financial Results

Feb 11 2026Yahoo Finance

Neurocrine Biosciences Q4 Earnings Announcement Scheduled

Feb 10 2026seekingalpha

Neurocrine Initiates Phase 2 Study for NBI-1065890 in Tardive Dyskinesia

Jan 26 2026PRnewswire

NBIX Events

No data

No data

NBIX Monitor News

Neurocrine Biosciences Reports Q4 Earnings Miss Amid Strong Sales Growth

Neurocrine Highlights INGREZZA Efficacy

NBIX Earnings Analysis

Neurocrine Biosciences Q3 2025: Earnings & Strategic Growth- Intellectia AI™

People Also Watch